Biotech

All Articles

Bicara, Zenas look for IPOs to push late-phase properties towards market

.Bicara Therapeutics and also Zenas Biopharma have actually offered clean impetus to the IPO market ...

Genentech to finalize cancer immunology study division

.Genentech will certainly close its cancer immunology study division, as well as unit mind as well a...

Kezar drops strong growth but to confirm its own worth in phase 1 test

.Kezar Life Sciences is dropping its own unpromising period 1 sound cyst medicine as the biotech goe...

Acelyrin drops izokibep, drops 3rd of staff

.Even with izokibep sustaining its newly found winning streak in the clinic, Acelyrin is actually no...

Rivus' stage 2 obesity-related cardiac arrest trial hits endpoint

.Rivus Pharmaceuticals has plumped up the customers of its fat-busting, muscle-sparing drug candidat...

Ovid standstills preclinical work, IV plan after soticlestat fall short

.Ovid Therapy already uncovered final month that it was trimming its headcount as the firm browses a...

Eli Lilly opens $700M nucleic acid R&ampD center in Boston Port

.Eli Lilly has actually opened up a $700 million R&ampD facility in the Boston Seaport, boosting its...

Boundless Bio helps make 'modest' layoffs five months after $100M IPO

.Just 5 months after getting a $100 million IPO, Boundless Bio is currently giving up some employees...

Halda's $126M will certainly evolve 'hold and also get rid of' lump medicines

.The first stages of oncology R&ampD aren't except appealing new modalities, and Halda Therapies is ...

Lykos 'remorses' not disclosing research study transgressions with author

.Psychopharmacology has actually drawn three articles regarding midstage medical trial records asses...